retatrutide glp-1 gip glucagon agonist Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing retatrutide - Diabetes In Control

0% to 15% of hairs are in telogen, the resting phase where old hairs fall out and new ones begin to grow

They enhance glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and reduce appetite, thereby contributing to glucose homeostasis and body weight regulation (29, 30)

A sustainable 8mg beats an intolerable 12mg every time

#Converged #MeaningfulBrands #OneHavas #GLP1 Havas Health Networks Post On Wednesday, November 13th, 2024, leaders from around the industry will gather at Havas NY offices to tackle this era of multi-industry disruption from GLP-1s

one is the biological process, while the other is a commercial product that uses it